Ireland
--:--IST
Clinical Trials in the EU / 2024-517923-38-00
Authorised, recruiting Phase I

A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment

2024-517923-38-00 · tracked via the Priya Life Science EU tracker
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
24/11/2025
Enrollment target
25
Sites
Czechia, Spain

Condition studied

Newly diagnosed and/or previously treated IDH1-mutated malignancies

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-517923-38-00 on CTIS ↗ ← All trials in the EU